| 1 |
李咏生，孙建国，李梦侠，等. 第三代EGFR-TKI耐药后诊疗策略专家共识[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(2): 145-155.
|
| 2 |
徐康乔，张国清，严智亮，等. 外泌体环状RNA与肺癌关系[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(2): 334-337.
|
| 3 |
中华医学会肿瘤学分会，中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2022版)[J]. 中华肿瘤杂志，2022, 44(6): 457-490.
|
| 4 |
Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3.
|
| 5 |
Frese KK, Simpson KL, Dive C. Small cell lung cancer enters the era of precision medicine[J]. Cancer Cell, 2021, 39(3): 297-299.
|
| 6 |
Andrini E, Marchese PV, De Biase D, et al. Large cell neuroendocrine carcinoma of the lung: Current understanding and challenges[J]. J Clin Med, 2022, 11(5): 1461.
|
| 7 |
Lowczak A, Kolasinska-Cwikla A, Osowiecka K, et al. Outcomes of patients with pulmonary large cell neuroendocrine carcinoma in Ⅰ-Ⅳ stage[J]. Medicina (Kaunas), 2021, 57(2): 118.
|
| 8 |
Gao S, Li N, Wang S, et al. Lung cancer in people's republic of China[J]. J Thorac Oncol, 2020, 15(10): 1567-1576.
|
| 9 |
Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality[J]. N Engl J Med, 2020, 383(7): 640-649.
|
| 10 |
Liu SM, Zheng MM, Pan Y, et al. Emerging evidence and treatment paradigm of non-small cell lung cancer[J]. J Hematol Oncol, 2023, 16(1): 40.
|
| 11 |
Wang Q, Gumus ZH, Colarossi C, et al. SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection[J]. J Thorac Oncol, 2023, 18(1): 31-46.
|
| 12 |
Dawkins JBN, Webster RM. The small-cell lung cancer drug market[J]. Nat Rev Drug Discov, 2020, 19(8): 507-508.
|
| 13 |
Petty WJ, Paz-Ares L. Emerging strategies for the treatment of small cell lung cancer: a review[J]. JAMA Oncol, 2023, 9(3): 419-429.
|
| 14 |
Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: First-line and second-line treatment options[J]. J Clin Oncol, 2022, 40(6): 671-680.
|
| 15 |
Bilski M, Mertowska P, Mertowski S, et al. The role of conventionally fractionated radiotherapy and stereotactic radiotherapy in the treatment of carcinoid tumors and large-cell neuroendocrine cancer of the lung[J]. Cancers (Basel), 2021, 14(1): 177.
|
| 16 |
Mohajeri MH, Brummer RJM, Rastall RA, et al. The role of the microbiome for human health: from basic science to clinical applications[J]. Eur J Nutrition, 2018, 57(Suppl 1): S1-S14.
|
| 17 |
Ogunrinola GA, Oyewale JO, Oshamika OO, et al. The human microbiome and its impacts on health[J]. Int J Microbiol, 2020, 2020: 8045646.
|
| 18 |
Raza MH, Gul K, Arshad A, et al. Microbiota in cancer development and treatment[J]. J Cancer Res Clin Oncol, 2019, 145(1): 49-63.
|
| 19 |
de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Global Health, 2020, 8(2): E180-E190.
|
| 20 |
Riquelme E, Zhang Y, Zhang L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes[J]. Cell, 2019, 178(4): 795-806.
|
| 21 |
Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020, 369(6510): 1481-1489.
|
| 22 |
Kovaleva OV, Romashin D, Zborovskaya IB, et al. Human lung microbiome on the way to cancer[J]. J Immunol Res, 2019, 2019: 1394191.
|
| 23 |
Maddi A, Sabharwal A, Violante T, et al. The microbiome and lung cancer[J]. J Thorac Dis, 2019, 11(1): 280-291.
|
| 24 |
Perrone F, Belluomini L, Mazzotta M, et al. Exploring the role of respiratory microbiome in lung cancer: a systematic review[J]. Crit Rev Oncol Hematol, 2021, 164: 103404.
|
| 25 |
Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health[J]. Nat Immunol, 2019, 20(10): 1279-1290.
|
| 26 |
Jin J, Gan Y, Liu H, et al. Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation[J]. Lung Cancer, 2019, 136: 129-135.
|
| 27 |
Wensel CR, Pluznick JL, Salzberg SL, et al. Next-generation sequencing: insights to advance clinical investigations of the microbiome[J]. J Clin Invest, 2022, 132(7): e154944.
|
| 28 |
Schlaberg R. Microbiome diagnostics[J]. Clin Chem, 2020, 66(1): 68-76.
|
| 29 |
Weinroth MD, Belk AD, Dean C, et al. Considerations and best practices in animal science 16S ribosomal RNA gene sequencing microbiome studies[J]. J Anim Sci, 2022, 100(2): skab346.
|
| 30 |
Lee SH, Sung JY, Yong D, et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions[J]. Lung Cancer, 2016, 102: 89-95.
|
| 31 |
Zhuo M, An T, Zhang C, et al. Characterization of microbiota in cancerous lung and the contralateral non-cancerous lung within lung cancer patients[J]. Front Oncol, 2020, 10: 1584.
|
| 32 |
Huang D, Su X, Yuan M, et al. The characterization of lung microbiome in lung cancer patients with different clinicopathology[J]. Am J Cancer Res, 2019, 9(9): 2047-2063.
|
| 33 |
Garrett WS. Cancer and the microbiota[J]. Science, 2015, 348(6230): 80-86.
|
| 34 |
Chen J, Domingue JC, Sears CL. Microbiota dysbiosis in select human cancers: Evidence of association and causality[J]. Sem Immunol, 2017, 32: 25-34.
|
| 35 |
Wang K, Huang Y, Zhang Z, et al. A preliminary study of microbiota diversity in saliva and bronchoalveolar lavage fluid from patients with primary bronchogenic carcinoma[J]. Med Sci Monit, 2019, 25: 2819-2834.
|
| 36 |
Fang X, Wei J, He X, et al. Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies[J]. Int J Cancer, 2018, 143(7): 1595-1603.
|
| 37 |
Budden KF, Gellatly SL, Wood DLA, et al. Emerging pathogenic links between microbiota and the gut-lung axis[J]. Nat Rev Microbiol, 2017, 15(1): 55-63.
|